Eisai's Alzheimer Drug Leqembi Receives EU Marketing Authorization

MT NewswiresApr 16 22:07 ET

Ikuyo, Stella Pharma, ETC.

*Toyota Industries <6201> will develop heat-resistant materials for emerging and space industries in collaboration with Tohoku Universities (Nikkankogyo, page 3) -○*Eisai <4523> has obtained sales approval for its Alzheimer's treatment in the European Index (Nikkankogyo, page 3) -○*Toyota Gosei <7282> is implementing 'just-in-time' supply with 96 pickups a day, automating collection (Nikkankogyo, page 8) -○*Sumitomo Rubbers <5110> is producing hydrogen 24 hours a day and reducing CO2 emissions in the tire vulcanization process (Nikkankogyo, page 8) -○*Yamaha Motor <7272> has partnered with British Rollers in international EV races.

Fisco JapanApr 16 19:13 ET

List of convertible stocks (Part 1) [List of Parabolic Signal convertible stocks]

○ List of stocks with Buy switch Market Code Stock Name Closing Price SAR Main Board <1332> Nissui 851 795 <1861> Kumagai Gumi 39603595 <1873> Japan House HD 321297 <1963> JGC Holdings Corporation 1051941 <2374> Centcare HD 764687 <2975> Star Mica Holdings 945786 <3028> Alpen 23352137 <3

Fisco JapanApr 16 18:41 ET

Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion

BenzingaApr 16 13:26 ET

Spot information for individual stocks (1)

Japan Pharmaceutical <3341.T> reaches its year-to-date high. The bidding process for privatization has begun. FDK <6955.T> continues to rise for five consecutive days. An upward revision of the performance plan for the fiscal year ending March 2025 was announced. UNBANK <8746.T> significantly continues to rise. The provision of Cryptos linked to the price of Gold has started. Eisai <4523.T> rises for three consecutive days. 'Lecanemab' has obtained approval in the EU (European Index) as a treatment to suppress the progression of early Alzheimer's disease. ☆ The above article contains unverified information.

Kabushiki ShimbunApr 16 03:30 ET

Reported Earlier, European Commission Approves Eisai And Biogen's Leqembi As First Disease-Modifying Therapy For Early Alzheimer's

BenzingaApr 16 02:46 ET